- Home
- Equipment
- usa california
- in vivo studies
Refine by
In Vivo Studies Equipment Supplied In Usa California
5 equipment items found
Manufactured by:Tempo Bioscience, Inc based inSan Francisco, CALIFORNIA (USA)
Grown in vitro as a monolayer sheath, cardiomyocytes are connected by gap junction proteins that help synchronize contraction-relaxation cycles of the cardiomyocytes. Cardiomyocytes may be used in various in vitro or in vivo studies; transplantation into normal or diseased systems; cardiac toxicology studies; or cardiovascular developmental ...
Manufactured by:AnaSpec based inFremont, CALIFORNIA (USA)
Myelin Oligodendrocyte Glycoprotein (MOG) is a member of the immunoglobulin superfamily and is expressed exclusively in the central nervous system (CNS). Although MOG protein constitutes only 0.01-0.05% of the CNS myelin proteins, it was demonstrated that MOG protein is a crucial autoantigen for multiple sclerosis in humans and experimental autoimmune encephalomyelitis (EAE) in rodents and ...
Manufactured by:NuLiv Science based inBrea, CALIFORNIA (USA)
InnoSlim® is a pharmaceutical-grade glucose and lipid metabolic regulator through activation of the adiponectin and AMPK signaling ...
Manufactured by:Siolta Therapeutics based inSan Carlos, CALIFORNIA (USA)
Siolta’s Precision Symbiotics Platform enables rapid LBP development. A platform focused on translating microbiome science into novel therapeutics for a healthier world. Siolta’s patient-centric platform leverages our internal expertise in microbiome data analysis, machine learning, anaerobic microbiology, and translational studies to rationally design and optimize multi-strain live ...
Manufactured by:Qualigen Therapeutics, Inc. based inCarlsbad, CALIFORNIA (USA)
Qualigen licensed the G4 selective transcription inhibitor platform from University College London (UCL) in 2022. The licensed technology comprises lead compound QN-302 (formerly SOP1812) and back-up compounds that target regulatory regions of cancer genes that down-regulate gene expression in multiple cancer pathways. Developed by Dr. Stephen Neidle and his group at UCL, the G4 binding concept ...